Exosomes are nanoscale extracellular vesicles (typically 30–150 nanometers in diameter) naturally released by cells throughout the body, including mesenchymal stem cells. They function as intercellular messengers, carrying a concentrated cargo of bioactive molecules — growth factors, cytokines, microRNAs, messenger RNAs, and regulatory proteins — from one cell to another. This molecular cargo can reprogram recipient cell behavior, modulate immune responses, reduce inflammatory signaling, and support tissue repair processes.
In regenerative medicine for autism, exosome therapy delivers these powerful signaling molecules directly — without administering the living cells that produce them. This cell-free approach offers several distinctive characteristics: exosomes are non-replicating, non-tumorigenic, and — critically — can cross the blood-brain barrier to reach neural tissues that may be difficult to access through other therapeutic routes.
Exosome therapy for autism is investigational. While preclinical research and early clinical observations have shown promising signals in neuroinflammatory modulation, immune rebalancing, and cellular communication support, large-scale controlled studies are still underway. We present the current state of evidence transparently — including both what is promising and what remains under investigation — so families can make fully informed decisions.
